By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Nycomed GmbH et al. v. Apotex Inc. et al.
1:08-cv-00827; filed February 7, 2008 in the Northern District of Illinois
Infringement of U.S. Patent No. 6,780,881 ("Freeze-dried Pantoprazole Preparation and Pantoprazole Injection," issued August 24, 2004) (licensed to Wyeth) following a paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Wyeth's PROTONIX I.V. (pantoprazole sodium injection, used to treat gastroesophageal reflux disease). View the complaint here.
Novartis Corp. et al. v. Teva Pharmaceuticals USA, Inc.
2:08-cv-00686; filed February 7, 2008 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,162,802 ("Synergistic Combination Therapy Using Benazepril and Amlodipine for the Treatment of Cardiovascular Disorders and Compositions Therefor," issued December 19, 2000) following a paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Novartis' Lotrel® (amlodipine besylate/benazepril hydrochloride, used to treat hypertension). View the complaint here. [NB: Novartis and Teva are already involved in a litigation over this product; this action is directed to a different dosage strength.]
Orion Corp. v. Sun Pharmaceutical Industries Ltd.
3:08-cv-00720; filed February 7, 2008 in the District Court of New Jersey
Infringement of U.S. Patent No. 5,446,194 ("Pharmacologically Active Catechol Derivatives," issued August 29, 1995) following a paragraph IV certification as part of Sun's filing of an ANDA to manufacture a generic version of Orion's Stalevo® (marketed by Novartis in the U.S.) (entacapone, levodopa, and carbidopa mixture, used to treat Parkinson's disease). View the complaint here.
Comments